HPLC–MS/MS-based quantification of human monoclonal antibodies targeting SARS-CoV-2 in the presence of endogenous SARS-CoV-2 antibodies in human serum-Reference-Cited by-同舟云学术

HPLC–MS/MS-based quantification of human monoclonal antibodies targeting SARS-CoV-2 in the presence of endogenous SARS-CoV-2 antibodies in human serum

Published:2024-06-21 Issue:19 Volume:416 Page:4383-4396
ISSN:1618-2642
Container-title:Analytical and Bioanalytical Chemistry
language:en
Short-container-title:Anal Bioanal Chem

Author:

Schäfer Alexander,Sagelsdorff Peter,Hock Björn,Bhuyan Prakash,Moullan Norman,Siethoff Christoph

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00216-024-05375-w.pdf

Reference14 articles.

1. Huang Y, Yang C, Xu XF, Xu W, Liu SW. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin. 2020;41(9):1141–9.

2. Fenwick C, Turelli P, Perez L, Pellaton C, Esteves-Leuenberger L, Farina A, et al. A highly potent antibody effective against SARS-CoV-2 variants of concern. Cell Rep. 2021;37(2):109814.

3. Fenwick C, Turelli P, Ni D, Perez L, Lau K, Lana E, et al. SARS-CoV-2 Omicron potently neutralized by a novel antibody with unique Spike binding properties [Internet]. bioRxiv; 2022 [cited 2023 Apr 13]. p. 2022.03.18.484873. Available from: https://www.biorxiv.org/content/10.1101/2022.03.18.484873v1. Accessed 13 Apr 2023

4. Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IWL, Sproule TJ, et al. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol. 2010;28(2):157.

5. Moullan N, Asiago J, Stecco K, Hadi S, Albizem M, Tieu H, et al. A first-in-human randomized study to assess the safety, tolerability, pharmacokinetics, and neutralization profile of two investigational long-acting anti-sarS-CoV-2 monoclonal antibodies. Infect Dis Ther. 2024;13(1):173–87.